What is Sarepta Therapeutics, Inc.'s investing cash flow?

Sarepta Therapeutics, Inc. (SRPT) reported investing cash flow of -$134.39M in Q1 2026.

How has Sarepta Therapeutics, Inc.'s investing cash flow changed year-over-year?

Sarepta Therapeutics, Inc.'s investing cash flow increased by 53.8% year-over-year, from -$291.18M to -$134.39M.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Sarepta Therapeutics, Inc. SRPT Investing Cash Flow

Investing Cash Flow at other companies

PfizerPFE

$785M-76.0%

Regeneron PharmaceuticalsREGN

-$428.9M-166%

BioMarin PharmaceuticalsBMRN

$725.53M+2,669%

PTC TherapeuticsPTCT

-$93.74M+49.2%

InsmedINSM

$265.52M+230%

Capricor TherapeuticsCAPR

-$154.64M-747%

Other financials

Income statement

See full

Revenue$730.8M-1.9%

Operating income-$300.4M-961%

Net income$331.0M+174%

EPS (diluted)-$4.60-1,343%

Balance sheet

See full

Cash & equivalents$464.5M+92.8%

Total debt$198.5M-3.4%

Total equity$1.5B+31.7%

Total assets$3.2B-8.3%

Cash flow

See full

Operating cash flow-$202.7M+65.3%

CapEx$2.1M-95.2%

Free cash flow-$204.8M+67.3%

Valuation

See full

Market cap$1.76B-63.1%

Profitability

See full

Operating margin-50.8%-1.6pp

Net margin4.6%+2.4pp

FCF margin-28.7%-9.2pp

Returns & leverage

See full

Return on equity-23.6%-28.5pp

Debt / equity0.1×0.0×

Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s investing cash flow?: Sarepta Therapeutics, Inc. (SRPT) reported investing cash flow of -$134.39M in Q1 2026.
How has Sarepta Therapeutics, Inc.'s investing cash flow changed year-over-year?: Sarepta Therapeutics, Inc.'s investing cash flow increased by 53.8% year-over-year, from -$291.18M to -$134.39M.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.